SCLC. At 5 years, 108 (16%) patients were alive; 66 males, 42 females. Mean age of survivors at treatment 67 years, median ECOG PS 1. SCLC for accounted 32 cases (18% total SCLC); NSCLC for accounted 76 cases (15% total NSCLC). SCLC (n¼32 limited-stage) were managed with sequential chemoradiotherapy (n¼20), concurrent chemoradiation (n¼12). NSCLC (n¼37 stage I; n¼9 stage II; n¼27 stage III; n¼3 stage IV) were managed with radiotherapy alone (n¼47), sequential chemoradiotherapy (n¼19), concurrent chemoradiotherapy (n¼7), SABR (n¼5). With 80 months total median follow-up 16 (15%) patients surviving 5 years relapsed, 14 NSCLC (2.7% total treated radically), 2 SCLC (1.9% total treated radically). Of 23 patients reaching the 5-year time-point and thereafter developing a further malignancy, 4 were cases of second lung primary. Conclusion: Approximately 1 in 6 patients (all-comers) survived for 5 years after radical radiotherapy. Approximately 1 in 6 patients with 5 year DFS will later go on to relapse, suggesting that such patients should receive active follow-up.
Background: Kilo-voltage cone beam computed tomography (kV-CBCT) allows for tumor localization and response assessment during definitive chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC). Previously we have analyzed patients with LA-NSCLC treated with definitive CRT accompanied with daily CBCT in our department and found that significant primary tumor volume loss occurs relatively early during treatment; and that greater tumor volume loss during treatment correlates with improved disease control and overall survival. It is not a standard practice to re-simulate patients for smaller target volume; but decreased tumor volume and consequent increase in air density could lead to increased radiation dose to the surrounding normal tissue such as the spinal cord. We hypothesize that increased air density secondary to tumor size reduction leads to increased dose to normal tissue including spinal cord, heart, esophagus and normal lung. Method: kV-CBCT images were imported to Eclipse treatment planning system. Primary tumors were re-contoured, and all normal tissue structures were readjusted based on the new images. Doses to the spinal cord, esophagus, normal lung, original planning target volume (PTV) as well as the new, smaller, PTV were re-calculated based on the original prescription dose and compared with the original plan by paired student t-test. The Acuros XB advanced dose calculation algorithm was used for all patients. Result: Nine patients with greater than 40% target volume reduction after 4 weeks of CRT were analyzed. There is a mean size reduction of 425.1 cc (55.6%) in PTV (p¼0.002). Mean dose to the new PTV is 50 cGy (0.8%) less than the prescription dose (average 6088 cGy) (p¼0.07). 0.03 cc of PTV receiving the highest dose is 110 cGy (1.8%) less than originally planned. There is no significant dose difference to the normal tissue, including esophagus (D0.03cc, DMean, V105%, V50 Gy and V60 Gy), heart (D0.03cc, DMean, V30Gy and V45Gy), ipsilateral lung (DMean, V5Gy, V10 Gy, V20 Gy, V30 Gy) and total lung (DMean, V5Gy, V10 Gy, V20 Gy, V30 Gy). Conclusion: Despite significant primary tumor size reduction, there is no clinically significant difference in dose delivered to the primary tumor or to the radiation sensitive critical organs. Therefore the orinigal treatment plan can be safely used.
P3.17-21 Surgical Treatment for Centrally Located or Hilar Invasive Locally Advanced Lung Cancer M. Yamashita, 1 Y. Maki, 1 R. Sugimoto, 1 T. Ueno, 1 S. Toyooka 2 1 Shikoku Cancer Center, Matsuyama/JP, 2 Okayama University Graduate School of Medicine, Okayama/JP Background: In cases of centrally located or hilar invasive lung cancer(CLHILC), it is quite difficult to decide the treatment strategy whether pneumonectomy, sleeve-lobectomy and/or pulmonary angioplastic procedure, or lobectomy is necessary or not. Especially in the patients with inadequate pulmonary functions, the treatment strategy is hard to be decided. To clarify the surgical outcomes for CLHILC, we retrospectively investigated our experiences in Setouchi Lung Cancer Study Group (SLCG). Method: In order to show the clinical results of (CLHILC), we retrospectively investigated the patients' medical records from January 2010 to December 2011 in SLCG. The definition of CLHILC; clinical tumor size is more than 3cm (T2 or more) and located in main bronchus or lobar orifice, or hilar nodal invasion is shown around lobar bronchial orifice or pulmonary arterial branch without mediastinal nodal metastasis. That is, the simple lobectomy is not easy or inadequate to complete resection for CLHILC. Result: Ninety-seven patients' records were collected, the men were 78, the mean age was 67. Twenty-four cases underwent preoperative treatment (induction chemotherapy in 8, induction chemoradiotherapy in 13, and radiotherapy in 3 cases). Except 1 exploratory thoracotomy cases, the surgical procedure was as following; lobectomy in 37, lobectomy with broncho-vascular plasty in 4, bronchoplasty in 11 and pulmonary angioplasty in 16, bilobectomy in 12, and pneumonectomy in 15 cases. The post-operative complications were occurred in 39 cases (40%), and there were 2 30-days mortal cases. The survival rate was 65% at 3 years and 60% at 5 years. Conclusion: We reviewed CLHILC in SLCS Group and showed the surgical procedure variety, the morbidity and survival rate. The pneumonectomy was performed in 15% and the complicated surgical procedure such as broncho-vasucular platy were chosen in 30% with acceptable morbidity and mortality. Keywords: Hilar invasive lung cancer, Pneumonectomy, Broncho-vascular plastic surgery P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/ Gemcitabine as Induction in Resectable NSCLC
